High-tech Lugu March 16, 2022 (Li Liting)On March 15, 2022, a research team from the Foreign Affairs Office of the Changsha Municipal Party Committee (City Government Hong Kong and Macao Affairs Office) visited Changsha High-tech Zone visited two pharmaceutical companies, Jiuzhitang and Fangsheng Pharmaceutical, to conduct research on supporting the “going out” of Changsha’s traditional Chinese medicine industry.
The research team walked into Jiuzhitang, and listened to the report of the relevant person in charge of Jiuzhitang on the basic situation of the company, the current situation and needs of enterprise innovation, development planning, etc., learned about the 300-year development history of Jiuzhitang, and visited the exhibition hall of Jiuzhitang and production lines. According to reports, seven Chinese patent medicine products, Liuwei Dihuang Pills, Qiju Dihuang Pills, Guipi Pills, Xiaoyao Pills, Zhibai Dihuang Pills, Buzhong Yiqi Pills, and Guifu Dihuang Pills produced by Jiuzhitang have obtained the Brazilian National Health Supervision. The company has already opened up the Brazilian market and hopes to further develop overseas markets with the help of government resources, and send more high-quality Chinese medicine products of the company abroad.
Then, the research team visited Fangsheng Pharmaceutical’s R&D center to learn about the company’s development history and main products. According to reports, Fangsheng Pharmaceutical takes “new drug research and development capabilities” as its core competitive advantage, and has realized the management of the entire value chain of pharmaceutical research, clinical research, consistency evaluation, production and sales in the field of new drug research and development. As a national technology innovation demonstration enterprise, Fangsheng has obtained 124 product approvals with the approval number of the National Pharmaceutical Approval, 20 national new drug certificates, 39 Chinese invention patents, and 1 international patent, and has successfully developed cardiovascular and cerebrovascular, pediatrics , gynecology, orthopedics and other major brands of products.
The research team praised the development of pharmaceutical enterprises in the high-tech zone, and said that they will further leverage their resource advantages and effectively promote the “going out” of the traditional Chinese medicine industry.
On March 15, a research group from the Foreign Affairs Office of the Changsha Municipal Party Committee (Hong Kong and Macao Affairs Office of the Municipal Government) visited Changsha High-tech Zone. Photo by Li Liting
The research team visited Fangsheng Pharmaceutical R&D Center. Photo by Li Liting